CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4 enrolled
Drug / intervention
Sildenafil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02414204
NCT02414204N/ACompleted
CompareCT.gov

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

University of Alabama at Birmingham·interventional·Posted Apr 10, 2015·Updated Aug 12, 2019

In Brief

A clinical study evaluating Sildenafil and Placebo for Improve Endothelial Function and Decrease Vascular Stenosis. Completed, enrolled 4 participants across 1 site.

Detailed Summary

Patients with stage IV and V chronic kidney disease and end stage renal disease requiring hemodialysis at University of Alabama at Birmingham (UAB) Dialysis Clinics will be recruited from the UAB Vascular Access Clinic, which has been the site for recruitment of patients requiring new vascular access for the last 10 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImprove Endothelial Function and Decrease Vascular Stenosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 10, 2015
Enrollment StartApr 1, 2015
Primary CompletionJun 30, 2017
Study CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.2 years ago

Interventions

Sildenafildrug

Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.

Placeboother

Placebo will be over encapsulated to identical to drug comparison